This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

CorMedix Announces SPA Agreement With FDA For Phase 3 Trial In The Prevention Of Contrast-Induced Acute Kidney Injury Study With CRMD001 (A Proprietary Formulation Of Deferiprone)

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, announced it has received a Special Protocol – Agreement letter from the U.S. Food and Drug Administration (“FDA”) regarding a Special Protocol Assessment (“SPA”) on the design of a pivotal Phase 3 trial for the Company’s oral formulation of CRMD001 in the prevention of Contrast-Induced Acute Kidney Injury (“CI-AKI”). This SPA takes into consideration a modification to the dosing regimen contained in the previously submitted protocol.

CI-AKI, also referred to as Contrast Induced Nephropathy (“CIN”), with its associated morbidity and mortality, each year afflicts about one-third of the approximate 325,000 high risk patients with Chronic Kidney Disease (“CKD”) in the U.S. who undergo angiography for vascular imaging. If effective, CRMD001 treatment could significantly reduce the occurrence of CIN and its complications.

The Phase 3 clinical study of CRMD001 to be conducted under the SPA is planned for approximately 800 patients in approximately 80 centers worldwide. The planned study will be randomized, double-blind and placebo-controlled, with patients evenly divided into two groups: CRMD001 and placebo. The study will assess the efficacy and safety of CRMD001 in the reduction of morbidity and mortality in patients with CKD undergoing diagnostic or interventional cardiac procedures and receiving an iodinated radiocontrast agent. The study will have a primary composite clinical endpoint that includes: death, dialysis, myocardial infarction, stroke, congestive heart failure and hospitalization. The hypothesis is that CRMD001 will significantly reduce the composite event rate compared to placebo. The study also includes secondary and exploratory endpoints which will include changes in serum creatinine and serum cystatin C, as well as other biomarkers. CRMD01 or placebo will be administered orally for 8 days.

CorMedix plans to begin patient enrollment in this Phase 3 study during the first half of 2012, pending results of its Phase 2 study for which patient recruitment was recently completed; results of such Phase 2 study are expected to be reported in the second half of 2011.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs